nodes	percent_of_prediction	percent_of_DWPC	metapath
Metolazone—Quinethazone—SLC12A2—skin cancer	0.0437	1	CrCbGaD
Metolazone—Purpura—Temozolomide—skin cancer	0.00465	0.00486	CcSEcCtD
Metolazone—Chills—Imiquimod—skin cancer	0.00464	0.00485	CcSEcCtD
Metolazone—Cough—Vemurafenib—skin cancer	0.00461	0.00482	CcSEcCtD
Metolazone—Oropharyngeal pain—Docetaxel—skin cancer	0.00452	0.00472	CcSEcCtD
Metolazone—Arthralgia—Vemurafenib—skin cancer	0.0045	0.0047	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Dactinomycin—skin cancer	0.00446	0.00467	CcSEcCtD
Metolazone—Vomiting—Vismodegib—skin cancer	0.00444	0.00464	CcSEcCtD
Metolazone—Rash—Vismodegib—skin cancer	0.0044	0.0046	CcSEcCtD
Metolazone—Dermatitis—Vismodegib—skin cancer	0.0044	0.0046	CcSEcCtD
Metolazone—Back pain—Imiquimod—skin cancer	0.00436	0.00456	CcSEcCtD
Metolazone—Lethargy—Fluorouracil—skin cancer	0.00421	0.00441	CcSEcCtD
Metolazone—Ill-defined disorder—Imiquimod—skin cancer	0.00418	0.00437	CcSEcCtD
Metolazone—Nausea—Vismodegib—skin cancer	0.00414	0.00433	CcSEcCtD
Metolazone—Agitation—Imiquimod—skin cancer	0.00414	0.00433	CcSEcCtD
Metolazone—Dry skin—Temozolomide—skin cancer	0.00411	0.0043	CcSEcCtD
Metolazone—Hypokalaemia—Temozolomide—skin cancer	0.00408	0.00427	CcSEcCtD
Metolazone—Malaise—Imiquimod—skin cancer	0.00406	0.00425	CcSEcCtD
Metolazone—Syncope—Imiquimod—skin cancer	0.00404	0.00422	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Temozolomide—skin cancer	0.00404	0.00422	CcSEcCtD
Metolazone—Palpitations—Imiquimod—skin cancer	0.00398	0.00416	CcSEcCtD
Metolazone—Loss of consciousness—Imiquimod—skin cancer	0.00396	0.00414	CcSEcCtD
Metolazone—Cough—Imiquimod—skin cancer	0.00393	0.00411	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00393	0.00411	CcSEcCtD
Metolazone—Skin exfoliation—Docetaxel—skin cancer	0.00392	0.0041	CcSEcCtD
Metolazone—Abdominal distension—Temozolomide—skin cancer	0.0039	0.00408	CcSEcCtD
Metolazone—Hypertension—Imiquimod—skin cancer	0.00389	0.00407	CcSEcCtD
Metolazone—Neuropathy—Docetaxel—skin cancer	0.00386	0.00403	CcSEcCtD
Metolazone—Chest pain—Imiquimod—skin cancer	0.00383	0.00401	CcSEcCtD
Metolazone—Arthralgia—Imiquimod—skin cancer	0.00383	0.00401	CcSEcCtD
Metolazone—Anxiety—Imiquimod—skin cancer	0.00382	0.004	CcSEcCtD
Metolazone—Discomfort—Imiquimod—skin cancer	0.00379	0.00396	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Dactinomycin—skin cancer	0.00379	0.00396	CcSEcCtD
Metolazone—Dry skin—Fluorouracil—skin cancer	0.00379	0.00396	CcSEcCtD
Metolazone—Dry mouth—Imiquimod—skin cancer	0.00375	0.00392	CcSEcCtD
Metolazone—Decreased appetite—Vemurafenib—skin cancer	0.00375	0.00392	CcSEcCtD
Metolazone—Fatigue—Vemurafenib—skin cancer	0.00372	0.00389	CcSEcCtD
Metolazone—Constipation—Vemurafenib—skin cancer	0.00369	0.00385	CcSEcCtD
Metolazone—Lightheadedness—Docetaxel—skin cancer	0.00367	0.00384	CcSEcCtD
Metolazone—Shock—Imiquimod—skin cancer	0.00362	0.00378	CcSEcCtD
Metolazone—Erectile dysfunction—Temozolomide—skin cancer	0.00357	0.00373	CcSEcCtD
Metolazone—Agranulocytosis—Dactinomycin—skin cancer	0.00356	0.00373	CcSEcCtD
Metolazone—Photosensitivity reaction—Temozolomide—skin cancer	0.00354	0.0037	CcSEcCtD
Metolazone—Anorexia—Imiquimod—skin cancer	0.0035	0.00366	CcSEcCtD
Metolazone—Hyperglycaemia—Temozolomide—skin cancer	0.00349	0.00365	CcSEcCtD
Metolazone—Hepatitis—Dactinomycin—skin cancer	0.00343	0.00358	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.00342	0.00358	CcSEcCtD
Metolazone—Neuropathy peripheral—Temozolomide—skin cancer	0.00339	0.00354	CcSEcCtD
Metolazone—Swelling—Docetaxel—skin cancer	0.00338	0.00353	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00335	0.0035	CcSEcCtD
Metolazone—Insomnia—Imiquimod—skin cancer	0.00333	0.00348	CcSEcCtD
Metolazone—Paraesthesia—Imiquimod—skin cancer	0.0033	0.00345	CcSEcCtD
Metolazone—Chills—Bleomycin—skin cancer	0.0033	0.00345	CcSEcCtD
Metolazone—Somnolence—Imiquimod—skin cancer	0.00327	0.00342	CcSEcCtD
Metolazone—Photosensitivity reaction—Fluorouracil—skin cancer	0.00326	0.00341	CcSEcCtD
Metolazone—Erythema multiforme—Dactinomycin—skin cancer	0.00324	0.00339	CcSEcCtD
Metolazone—Dyspepsia—Imiquimod—skin cancer	0.00324	0.00338	CcSEcCtD
Metolazone—Decreased appetite—Imiquimod—skin cancer	0.0032	0.00334	CcSEcCtD
Metolazone—Hypersensitivity—Vemurafenib—skin cancer	0.00318	0.00332	CcSEcCtD
Metolazone—Fatigue—Imiquimod—skin cancer	0.00317	0.00331	CcSEcCtD
Metolazone—Pain—Imiquimod—skin cancer	0.00314	0.00329	CcSEcCtD
Metolazone—Neuropathy peripheral—Fluorouracil—skin cancer	0.00312	0.00326	CcSEcCtD
Metolazone—Hepatitis—Temozolomide—skin cancer	0.0031	0.00324	CcSEcCtD
Metolazone—Asthenia—Vemurafenib—skin cancer	0.00309	0.00323	CcSEcCtD
Metolazone—Chills—Dactinomycin—skin cancer	0.00308	0.00322	CcSEcCtD
Metolazone—Pruritus—Vemurafenib—skin cancer	0.00305	0.00319	CcSEcCtD
Metolazone—Lethargy—Docetaxel—skin cancer	0.00304	0.00318	CcSEcCtD
Metolazone—Feeling abnormal—Imiquimod—skin cancer	0.00303	0.00317	CcSEcCtD
Metolazone—Gastrointestinal pain—Imiquimod—skin cancer	0.00301	0.00314	CcSEcCtD
Metolazone—Epistaxis—Fluorouracil—skin cancer	0.003	0.00314	CcSEcCtD
Metolazone—Hyponatraemia—Docetaxel—skin cancer	0.00299	0.00313	CcSEcCtD
Metolazone—Agranulocytosis—Fluorouracil—skin cancer	0.00297	0.00311	CcSEcCtD
Metolazone—Ill-defined disorder—Bleomycin—skin cancer	0.00297	0.0031	CcSEcCtD
Metolazone—Anaemia—Bleomycin—skin cancer	0.00296	0.00309	CcSEcCtD
Metolazone—Diarrhoea—Vemurafenib—skin cancer	0.00295	0.00308	CcSEcCtD
Metolazone—Erythema multiforme—Temozolomide—skin cancer	0.00293	0.00307	CcSEcCtD
Metolazone—Urticaria—Imiquimod—skin cancer	0.00292	0.00305	CcSEcCtD
Metolazone—Abdominal pain—Imiquimod—skin cancer	0.00291	0.00304	CcSEcCtD
Metolazone—Tinnitus—Temozolomide—skin cancer	0.00289	0.00302	CcSEcCtD
Metolazone—Malaise—Bleomycin—skin cancer	0.00289	0.00302	CcSEcCtD
Metolazone—Leukopenia—Bleomycin—skin cancer	0.00286	0.003	CcSEcCtD
Metolazone—Dizziness—Vemurafenib—skin cancer	0.00285	0.00298	CcSEcCtD
Metolazone—Cough—Bleomycin—skin cancer	0.00279	0.00292	CcSEcCtD
Metolazone—Chills—Temozolomide—skin cancer	0.00278	0.00291	CcSEcCtD
Metolazone—Ill-defined disorder—Dactinomycin—skin cancer	0.00277	0.0029	CcSEcCtD
Metolazone—Anaemia—Dactinomycin—skin cancer	0.00276	0.00288	CcSEcCtD
Metolazone—Vomiting—Vemurafenib—skin cancer	0.00274	0.00287	CcSEcCtD
Metolazone—Dry skin—Docetaxel—skin cancer	0.00273	0.00286	CcSEcCtD
Metolazone—Chest pain—Bleomycin—skin cancer	0.00272	0.00285	CcSEcCtD
Metolazone—Orthostatic hypotension—Docetaxel—skin cancer	0.00272	0.00285	CcSEcCtD
Metolazone—Rash—Vemurafenib—skin cancer	0.00272	0.00284	CcSEcCtD
Metolazone—Dermatitis—Vemurafenib—skin cancer	0.00272	0.00284	CcSEcCtD
Metolazone—Hypersensitivity—Imiquimod—skin cancer	0.00271	0.00283	CcSEcCtD
Metolazone—Headache—Vemurafenib—skin cancer	0.0027	0.00282	CcSEcCtD
Metolazone—Discomfort—Bleomycin—skin cancer	0.00269	0.00281	CcSEcCtD
Metolazone—Malaise—Dactinomycin—skin cancer	0.00269	0.00281	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.00268	0.00281	CcSEcCtD
Metolazone—Cramp muscle—Docetaxel—skin cancer	0.00268	0.00281	CcSEcCtD
Metolazone—Leukopenia—Dactinomycin—skin cancer	0.00267	0.00279	CcSEcCtD
Metolazone—Dysgeusia—Temozolomide—skin cancer	0.00264	0.00276	CcSEcCtD
Metolazone—Asthenia—Imiquimod—skin cancer	0.00264	0.00276	CcSEcCtD
Metolazone—Back pain—Temozolomide—skin cancer	0.00261	0.00273	CcSEcCtD
Metolazone—Pruritus—Imiquimod—skin cancer	0.0026	0.00272	CcSEcCtD
Metolazone—Nausea—Vemurafenib—skin cancer	0.00256	0.00268	CcSEcCtD
Metolazone—Thrombocytopenia—Bleomycin—skin cancer	0.00256	0.00267	CcSEcCtD
Metolazone—Vision blurred—Temozolomide—skin cancer	0.00254	0.00266	CcSEcCtD
Metolazone—Diarrhoea—Imiquimod—skin cancer	0.00252	0.00263	CcSEcCtD
Metolazone—Discomfort—Dactinomycin—skin cancer	0.00251	0.00263	CcSEcCtD
Metolazone—Ill-defined disorder—Temozolomide—skin cancer	0.0025	0.00262	CcSEcCtD
Metolazone—Anaemia—Temozolomide—skin cancer	0.00249	0.00261	CcSEcCtD
Metolazone—Anorexia—Bleomycin—skin cancer	0.00249	0.0026	CcSEcCtD
Metolazone—Agitation—Temozolomide—skin cancer	0.00248	0.00259	CcSEcCtD
Metolazone—Malaise—Temozolomide—skin cancer	0.00243	0.00255	CcSEcCtD
Metolazone—Dizziness—Imiquimod—skin cancer	0.00243	0.00254	CcSEcCtD
Metolazone—Vertigo—Temozolomide—skin cancer	0.00243	0.00254	CcSEcCtD
Metolazone—Leukopenia—Temozolomide—skin cancer	0.00242	0.00253	CcSEcCtD
Metolazone—Palpitations—Temozolomide—skin cancer	0.00239	0.00249	CcSEcCtD
Metolazone—Thrombocytopenia—Dactinomycin—skin cancer	0.00238	0.00249	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00238	0.00249	CcSEcCtD
Metolazone—Cough—Temozolomide—skin cancer	0.00236	0.00246	CcSEcCtD
Metolazone—Paraesthesia—Bleomycin—skin cancer	0.00235	0.00245	CcSEcCtD
Metolazone—Vision blurred—Fluorouracil—skin cancer	0.00234	0.00245	CcSEcCtD
Metolazone—Vomiting—Imiquimod—skin cancer	0.00234	0.00244	CcSEcCtD
Metolazone—Hypertension—Temozolomide—skin cancer	0.00233	0.00244	CcSEcCtD
Metolazone—Anorexia—Dactinomycin—skin cancer	0.00232	0.00243	CcSEcCtD
Metolazone—Rash—Imiquimod—skin cancer	0.00232	0.00242	CcSEcCtD
Metolazone—Dermatitis—Imiquimod—skin cancer	0.00232	0.00242	CcSEcCtD
Metolazone—Headache—Imiquimod—skin cancer	0.0023	0.00241	CcSEcCtD
Metolazone—Anaemia—Fluorouracil—skin cancer	0.0023	0.0024	CcSEcCtD
Metolazone—Arthralgia—Temozolomide—skin cancer	0.0023	0.0024	CcSEcCtD
Metolazone—Anxiety—Temozolomide—skin cancer	0.00229	0.00239	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.00228	0.00238	CcSEcCtD
Metolazone—Discomfort—Temozolomide—skin cancer	0.00227	0.00237	CcSEcCtD
Metolazone—Decreased appetite—Bleomycin—skin cancer	0.00227	0.00237	CcSEcCtD
Metolazone—Neuropathy peripheral—Docetaxel—skin cancer	0.00225	0.00235	CcSEcCtD
Metolazone—Dry mouth—Temozolomide—skin cancer	0.00225	0.00235	CcSEcCtD
Metolazone—Pain—Bleomycin—skin cancer	0.00223	0.00234	CcSEcCtD
Metolazone—Leukopenia—Fluorouracil—skin cancer	0.00223	0.00233	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00222	0.00232	CcSEcCtD
Metolazone—Nausea—Imiquimod—skin cancer	0.00218	0.00228	CcSEcCtD
Metolazone—Epistaxis—Docetaxel—skin cancer	0.00217	0.00227	CcSEcCtD
Metolazone—Thrombocytopenia—Temozolomide—skin cancer	0.00216	0.00226	CcSEcCtD
Metolazone—Feeling abnormal—Bleomycin—skin cancer	0.00215	0.00225	CcSEcCtD
Metolazone—Agranulocytosis—Docetaxel—skin cancer	0.00214	0.00224	CcSEcCtD
Metolazone—Chest pain—Fluorouracil—skin cancer	0.00212	0.00221	CcSEcCtD
Metolazone—Decreased appetite—Dactinomycin—skin cancer	0.00212	0.00221	CcSEcCtD
Metolazone—Fatigue—Dactinomycin—skin cancer	0.0021	0.0022	CcSEcCtD
Metolazone—Anorexia—Temozolomide—skin cancer	0.0021	0.0022	CcSEcCtD
Metolazone—Discomfort—Fluorouracil—skin cancer	0.00209	0.00219	CcSEcCtD
Metolazone—Pain—Dactinomycin—skin cancer	0.00208	0.00218	CcSEcCtD
Metolazone—Urticaria—Bleomycin—skin cancer	0.00207	0.00217	CcSEcCtD
Metolazone—Hepatitis—Docetaxel—skin cancer	0.00206	0.00216	CcSEcCtD
Metolazone—Feeling abnormal—Dactinomycin—skin cancer	0.00201	0.0021	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Temozolomide—skin cancer	0.00201	0.0021	CcSEcCtD
Metolazone—Insomnia—Temozolomide—skin cancer	0.00199	0.00208	CcSEcCtD
Metolazone—Gastrointestinal pain—Dactinomycin—skin cancer	0.00199	0.00208	CcSEcCtD
Metolazone—Thrombocytopenia—Fluorouracil—skin cancer	0.00199	0.00208	CcSEcCtD
Metolazone—Paraesthesia—Temozolomide—skin cancer	0.00198	0.00207	CcSEcCtD
Metolazone—Somnolence—Temozolomide—skin cancer	0.00196	0.00205	CcSEcCtD
Metolazone—Erythema multiforme—Docetaxel—skin cancer	0.00195	0.00204	CcSEcCtD
Metolazone—Dyspepsia—Temozolomide—skin cancer	0.00194	0.00203	CcSEcCtD
Metolazone—Anorexia—Fluorouracil—skin cancer	0.00193	0.00202	CcSEcCtD
Metolazone—Abdominal pain—Dactinomycin—skin cancer	0.00193	0.00201	CcSEcCtD
Metolazone—Hypersensitivity—Bleomycin—skin cancer	0.00192	0.00201	CcSEcCtD
Metolazone—Decreased appetite—Temozolomide—skin cancer	0.00192	0.002	CcSEcCtD
Metolazone—Fatigue—Temozolomide—skin cancer	0.0019	0.00199	CcSEcCtD
Metolazone—Pain—Temozolomide—skin cancer	0.00188	0.00197	CcSEcCtD
Metolazone—Constipation—Temozolomide—skin cancer	0.00188	0.00197	CcSEcCtD
Metolazone—Asthenia—Bleomycin—skin cancer	0.00187	0.00196	CcSEcCtD
Metolazone—Chills—Docetaxel—skin cancer	0.00185	0.00193	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.00185	0.00193	CcSEcCtD
Metolazone—Pruritus—Bleomycin—skin cancer	0.00185	0.00193	CcSEcCtD
Metolazone—Insomnia—Fluorouracil—skin cancer	0.00184	0.00192	CcSEcCtD
Metolazone—Paraesthesia—Fluorouracil—skin cancer	0.00182	0.00191	CcSEcCtD
Metolazone—Feeling abnormal—Temozolomide—skin cancer	0.00182	0.0019	CcSEcCtD
Metolazone—Somnolence—Fluorouracil—skin cancer	0.0018	0.00189	CcSEcCtD
Metolazone—Gastrointestinal pain—Temozolomide—skin cancer	0.0018	0.00188	CcSEcCtD
Metolazone—Hypersensitivity—Dactinomycin—skin cancer	0.00179	0.00188	CcSEcCtD
Metolazone—Dyspepsia—Fluorouracil—skin cancer	0.00179	0.00187	CcSEcCtD
Metolazone—Decreased appetite—Fluorouracil—skin cancer	0.00176	0.00185	CcSEcCtD
Metolazone—Dysgeusia—Docetaxel—skin cancer	0.00176	0.00184	CcSEcCtD
Metolazone—Urticaria—Temozolomide—skin cancer	0.00175	0.00183	CcSEcCtD
Metolazone—Asthenia—Dactinomycin—skin cancer	0.00175	0.00183	CcSEcCtD
Metolazone—Abdominal pain—Temozolomide—skin cancer	0.00174	0.00182	CcSEcCtD
Metolazone—Back pain—Docetaxel—skin cancer	0.00174	0.00182	CcSEcCtD
Metolazone—Pain—Fluorouracil—skin cancer	0.00174	0.00182	CcSEcCtD
Metolazone—Muscle spasms—Docetaxel—skin cancer	0.00173	0.0018	CcSEcCtD
Metolazone—Feeling abnormal—Fluorouracil—skin cancer	0.00167	0.00175	CcSEcCtD
Metolazone—Diarrhoea—Dactinomycin—skin cancer	0.00167	0.00174	CcSEcCtD
Metolazone—Vomiting—Bleomycin—skin cancer	0.00166	0.00174	CcSEcCtD
Metolazone—Anaemia—Docetaxel—skin cancer	0.00166	0.00173	CcSEcCtD
Metolazone—Rash—Bleomycin—skin cancer	0.00165	0.00172	CcSEcCtD
Metolazone—Dermatitis—Bleomycin—skin cancer	0.00165	0.00172	CcSEcCtD
Metolazone—Hypersensitivity—Temozolomide—skin cancer	0.00162	0.0017	CcSEcCtD
Metolazone—Urticaria—Fluorouracil—skin cancer	0.00161	0.00169	CcSEcCtD
Metolazone—Syncope—Docetaxel—skin cancer	0.00161	0.00168	CcSEcCtD
Metolazone—Leukopenia—Docetaxel—skin cancer	0.00161	0.00168	CcSEcCtD
Metolazone—Palpitations—Docetaxel—skin cancer	0.00159	0.00166	CcSEcCtD
Metolazone—Asthenia—Temozolomide—skin cancer	0.00158	0.00165	CcSEcCtD
Metolazone—Loss of consciousness—Docetaxel—skin cancer	0.00158	0.00165	CcSEcCtD
Metolazone—Cough—Docetaxel—skin cancer	0.00157	0.00164	CcSEcCtD
Metolazone—Pruritus—Temozolomide—skin cancer	0.00156	0.00163	CcSEcCtD
Metolazone—Nausea—Bleomycin—skin cancer	0.00155	0.00162	CcSEcCtD
Metolazone—Hypertension—Docetaxel—skin cancer	0.00155	0.00162	CcSEcCtD
Metolazone—Vomiting—Dactinomycin—skin cancer	0.00155	0.00162	CcSEcCtD
Metolazone—Rash—Dactinomycin—skin cancer	0.00154	0.00161	CcSEcCtD
Metolazone—Chest pain—Docetaxel—skin cancer	0.00153	0.0016	CcSEcCtD
Metolazone—Arthralgia—Docetaxel—skin cancer	0.00153	0.0016	CcSEcCtD
Metolazone—Diarrhoea—Temozolomide—skin cancer	0.00151	0.00158	CcSEcCtD
Metolazone—Hypersensitivity—Fluorouracil—skin cancer	0.0015	0.00156	CcSEcCtD
Metolazone—Dry mouth—Docetaxel—skin cancer	0.00149	0.00156	CcSEcCtD
Metolazone—Dizziness—Temozolomide—skin cancer	0.00146	0.00152	CcSEcCtD
Metolazone—Nausea—Dactinomycin—skin cancer	0.00145	0.00151	CcSEcCtD
Metolazone—Shock—Docetaxel—skin cancer	0.00144	0.00151	CcSEcCtD
Metolazone—Pruritus—Fluorouracil—skin cancer	0.00144	0.0015	CcSEcCtD
Metolazone—Thrombocytopenia—Docetaxel—skin cancer	0.00143	0.0015	CcSEcCtD
Metolazone—Vomiting—Temozolomide—skin cancer	0.0014	0.00146	CcSEcCtD
Metolazone—Anorexia—Docetaxel—skin cancer	0.0014	0.00146	CcSEcCtD
Metolazone—Rash—Temozolomide—skin cancer	0.00139	0.00145	CcSEcCtD
Metolazone—Diarrhoea—Fluorouracil—skin cancer	0.00139	0.00145	CcSEcCtD
Metolazone—Dermatitis—Temozolomide—skin cancer	0.00139	0.00145	CcSEcCtD
Metolazone—Headache—Temozolomide—skin cancer	0.00138	0.00144	CcSEcCtD
Metolazone—Dizziness—Fluorouracil—skin cancer	0.00134	0.0014	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Docetaxel—skin cancer	0.00133	0.0014	CcSEcCtD
Metolazone—Insomnia—Docetaxel—skin cancer	0.00133	0.00139	CcSEcCtD
Metolazone—Paraesthesia—Docetaxel—skin cancer	0.00132	0.00138	CcSEcCtD
Metolazone—Nausea—Temozolomide—skin cancer	0.00131	0.00137	CcSEcCtD
Metolazone—Somnolence—Docetaxel—skin cancer	0.0013	0.00136	CcSEcCtD
Metolazone—Vomiting—Fluorouracil—skin cancer	0.00129	0.00135	CcSEcCtD
Metolazone—Dyspepsia—Docetaxel—skin cancer	0.00129	0.00135	CcSEcCtD
Metolazone—Rash—Fluorouracil—skin cancer	0.00128	0.00134	CcSEcCtD
Metolazone—Dermatitis—Fluorouracil—skin cancer	0.00128	0.00134	CcSEcCtD
Metolazone—Decreased appetite—Docetaxel—skin cancer	0.00127	0.00133	CcSEcCtD
Metolazone—Headache—Fluorouracil—skin cancer	0.00127	0.00133	CcSEcCtD
Metolazone—Fatigue—Docetaxel—skin cancer	0.00126	0.00132	CcSEcCtD
Metolazone—Pain—Docetaxel—skin cancer	0.00125	0.00131	CcSEcCtD
Metolazone—Constipation—Docetaxel—skin cancer	0.00125	0.00131	CcSEcCtD
Metolazone—Feeling abnormal—Docetaxel—skin cancer	0.00121	0.00126	CcSEcCtD
Metolazone—Nausea—Fluorouracil—skin cancer	0.00121	0.00126	CcSEcCtD
Metolazone—Gastrointestinal pain—Docetaxel—skin cancer	0.0012	0.00125	CcSEcCtD
Metolazone—Abdominal pain—Docetaxel—skin cancer	0.00116	0.00121	CcSEcCtD
Metolazone—Hypersensitivity—Docetaxel—skin cancer	0.00108	0.00113	CcSEcCtD
Metolazone—Asthenia—Docetaxel—skin cancer	0.00105	0.0011	CcSEcCtD
Metolazone—Pruritus—Docetaxel—skin cancer	0.00104	0.00108	CcSEcCtD
Metolazone—Diarrhoea—Docetaxel—skin cancer	0.001	0.00105	CcSEcCtD
Metolazone—Dizziness—Docetaxel—skin cancer	0.000969	0.00101	CcSEcCtD
Metolazone—Vomiting—Docetaxel—skin cancer	0.000932	0.000974	CcSEcCtD
Metolazone—Rash—Docetaxel—skin cancer	0.000924	0.000966	CcSEcCtD
Metolazone—Dermatitis—Docetaxel—skin cancer	0.000923	0.000965	CcSEcCtD
Metolazone—Headache—Docetaxel—skin cancer	0.000918	0.00096	CcSEcCtD
Metolazone—Nausea—Docetaxel—skin cancer	0.00087	0.00091	CcSEcCtD
